Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage
Date:5/19/2011

higher rate of major GI bleeds and any GI bleeds compared to warfarin. In patients greater than or equal to 75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions.  These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer).  Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.  

For full PRADAXA prescribing information and medication guide, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About the Storage and Handling of PRADAXA

PRADAXA must be stored in its original packaging(1) and patients should not transfer the capsules to pill boxes or pill organizers. (7) Once the bottle is opened, the product must be used within 30 days.(1) Patients must close the bottle tightly immediately after removing one capsule(1) and must not alter the child-proof cap.(7) It is recommended that patients date the bottle to expire 30 days after first opening. When more than one bottle is dispensed, patients should only open one bottle at a time.(7) When packaged in a blister package, each capsule should only be removed at time of use.(1)

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer I
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
2. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
3. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
4. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
5. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
6. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
7. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
11. Mylan Launches First Generic Version of Amrix® Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced that it ... 30, 2015 results on Thursday, July 30, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has ... Imaging and by Application - Forecast to 2020" report to ... to reach $13.1 Billion in 2020 from an estimated $7.1 Billion ... market is dominated by North America , followed ... and Rest of the World (RoW). The cancer diagnostics market in ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... , , ... presented today from the SPIRIT III pivotal U.S. clinical ... XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase ... (TAXUS). At three years, XIENCE V demonstrated a 43 percent ...
... , REYKJAVIK, Iceland, September 20 ... of DNA-Based Testing to Identify Men at,Substantially Increased Risk, and ... deCODE genetics (Nasdaq: DCGN ) today announced ... Spain, the Netherlands and,the United States have today published the ...
Cached Medicine Technology:Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 2Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 3Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 4Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 5Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 6deCODE Discovers Four New Risk Factors for Prostate Cancer 2deCODE Discovers Four New Risk Factors for Prostate Cancer 3deCODE Discovers Four New Risk Factors for Prostate Cancer 4
(Date:7/4/2015)... ... , ... Chronic Neck Pain. Neck pain is no small problem. ... neck. Another 19% suffer from head, migraine, or facial pain, in some cases related ... American workers must deal with neck pain. Strategies for mitigating neck pain ...
(Date:7/3/2015)... ... 03, 2015 , ... On June 30th SEO authority and ... system called "Page One Engine" . The program, which has been hailed ... from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, publishing an ...
(Date:7/3/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national chief nursing officer recruitment for Jane Phillips Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... , ... First Choice Emergency Room , the largest network of independent ... new Medical Director of its Frisco facility. , “We are pleased to announce that ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:7/2/2015)... , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. ... The opening is the first sweetFrog store located in Mississippi. The premium frozen yogurt ... in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS 38652, ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2
... -- Air quality in America,s most polluted cities has improved ... from the American Lung Association. Even Los Angeles, famous ... 13 years, the association noted. Santa Fe, N.M. leads the ... nation. Despite progress in reducing the level of smog ...
... By Jenifer Goodwin HealthDay Reporter , ... drug reduced two signature characteristics of autism -- ... laboratory mice, new research finds. The drug, ... the brain that,s involved with activating neurons, or ...
... ranks as one cause of dandruff the embarrassing nuisance ... pointing scientists toward a much-needed new treatment for the condition,s ... report in ACS, Journal of Medicinal Chemistry . ... excessive shedding of dead skin cells from the scalp. In ...
... people can predict the actions of entire populations, according to ... the University of Oregon and the University of California at ... commercial market research and public health campaigns, and broaden the ... tool. As opposed to the wisdom of the crowd, ...
... Scientists are reporting that the mucus lining the stomachs of ... considered for use as broad-spectrum anti-viral agents to supplement baby ... products to protect against a range of viral infections. Their ... the report, Katharina Ribbeck and colleagues point out that mucus, ...
... Serena Gordon HealthDay Reporter , TUESDAY, April 24 ... for debilitating migraine headaches, but a new review finds that ... daily headaches. And, even then, the effect appears to only ... Botox (botulinum toxin A) was no help for people with ...
Cached Medicine News:Health News:Air Quality Improving in Many U.S. Cities: Report 2Health News:Air Quality Improving in Many U.S. Cities: Report 3Health News:Experimental Drug Eases Autistic Behaviors in Mice 2Health News:Experimental Drug Eases Autistic Behaviors in Mice 3Health News:Experimental Drug Eases Autistic Behaviors in Mice 4Health News:Small 'neural focus groups' predict anti-smoking ad success 2Health News:Small 'neural focus groups' predict anti-smoking ad success 3Health News:Botox Offers Little Relief for Migraine, Study Finds 2Health News:Botox Offers Little Relief for Migraine, Study Finds 3
... ,Oblique 45, ,Type 330 ,Straight, ,Konan ... setting the illumination between lenses for ... for use in ophthalmology and otorhinolaryngology, ... compact microscope can; an advanced zoom ...
... MedCath is the largest and most experienced ... networks in the United States. Mobile laboratories ... a daily basis, from one hospital to ... geographic area. Each mobile laboratory is fully ...
... The VersaPulse PowerSuite holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... to the progress and perfecting of endourological ... acquired a more strategic role in the ... this sector has certainly contributed towards simplifying ... pathologies that are becoming more and more ...
Medicine Products: